54856-23-4

Basic information

• Product Name: Betahistine mesylate
• Synonyms: BETAHISTINE MESYLATE;BETAHISTINE METHANESULFONATE;BETAHISTINE DIMESYLATE;BETAHISTINE DIMETHANESULFONATE;n-methyl-2-pyridineethylamine dimethanesulphonate;TENYL;Bethahistine methanesulfonate;Bethahistinemethanesulfonate
• CAS NO: 54856-23-4
• Molecular Formula: CH₄O₃S*C₈H₁₂N₂
• Molecular Weight: 328.41
• EINECS: 259-377-7
• Product Categories: Pharmaceutical raw material
• Mol File: 54856-23-4.mol
• Article Data: 0

Chemical Properties

• Melting Point: 112°C
• Boiling Point: 210.9 °C at 760 mmHg
• Flash Point: 96.7 °C
• Appearance: COA
• Vapor Pressure: 0.187mmHg at 25°C
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• Solubility: Very soluble in water, freely soluble in ethanol (96 per cent), very slightly soluble in 2-propanol.
• Water Solubility: almost transparency
• Stability: Hygroscopic
• CAS DataBase Reference: Betahistine mesylate(CAS DataBase Reference)
• NIST Chemistry Reference: Betahistine mesylate(54856-23-4)
• EPA Substance Registry System: Betahistine mesylate(54856-23-4)

Safety Data

• RTECS: UT2970200
• Hazardous Substances Data: 54856-23-4(Hazardous Substances Data)

Usage

Description

Betahistine mesylate is a histamine analog and H1 receptor agonist that serves as a vasodilator. It is an orally active histamine H1 receptor agonist and a H3 receptor antagonist, used for the study of rheumatoid arthritis (RA) and Meniere disease, as well as in vascular headaches. However, it may exacerbate bronchial asthma and peptic ulcers. Chemically, it is a white or almost white, crystalline powder that is very hygroscopic.

Uses

1. Used in Pharmaceutical Industry:
Betahistine mesylate is used as a vasodilator for improving blood flow in conditions like Meniere disease and vascular headaches. It helps in alleviating symptoms by increasing blood flow to the affected areas.
2. Used in Medical Research:
Betahistine mesylate is used as an H1 agonist and H3 receptor antagonist for the study of rheumatoid arthritis (RA), providing insights into the role of histamine receptors in the disease's progression and potential treatment options.
3. Used in Treatment of Meniere Disease:
Betahistine mesylate is used as a treatment for Meniere disease, a disorder of the inner ear that can cause vertigo, tinnitus, and hearing loss. It helps in managing the symptoms by improving blood flow to the inner ear.
4. Used in Treatment of Vascular Headaches:
Betahistine mesylate is used as a treatment for vascular headaches, such as migraines, by acting as a vasodilator and improving blood flow to the affected areas, thereby reducing the severity and frequency of headaches.

Indications

Betahistine mesylate is the mesylate salt form of Betahistine, a histamine analog and H3 receptor agonist that serves as a vasodilator. It is used in MENIERE DISEASE and in vascular headaches but may exacerbate bronchial asthma and peptic ulcers.

Safety Profile

Poison by subcutaneous route.Moderately toxic by ingestion and other routes. Whenheated to decomposition it emits toxic fumes of NOx andSOx.

in vitro

In Vitro: Betahistine mesylate (0-10 μM) inhibits [125I]iodoproxyfan binding to membranes of CHO (rH3(445)R) and CHO (hH3(445)R) cells with IC50 values of 1.9 μM and 3.3 μM, respectively. Lead to Ki values of 1.4 μM and 2.5 μM, respectively.Betahistine mesylate (0-10 μM) has a regulating function on cAMP formation in CHO (rH3(445)R), CHO (rH3(413)R), and CHO (hH3(445)R) cells. At low concentrations, Betahistine mesylate behaves an apparent inverse agonist, and progressively enhances cAMP formation with EC50 values of 0.1 nM, 0.05 nM and 0.3 nM, respectively. In contrast, at concentrations higher than 10 nM, Betahistine mesylate inhibits cAMP formation with an EC50 value of 0.1 μM in CHO (rH3(445)R) and full agonist activity.

Mode of action

Betahistine is indicated for the treatment of Meniere's disease and other audiovestibular disorders like vertigo and tinnitus. Betahistine is an analogue of histamine and an H1-receptor agonist. Stimulating the H1- receptors in the inner ear causes a vasodilatory effect and increased permeability in the blood vessels, resulting in reduced endolymphatic pressure. Betahistine acts by reducing the asymmetrical functioning of sensory vestibular organs and increasing vestibulocochlear blood flow, decreasing symptoms of vertigo, tinnitus, balance disorders, and hearing loss associated with Meniere's disease. Betahistine also acts as a histamine H3- receptor antagonist which causes an increased output of histamine, increase in the direct H1-agonist activity, and inhibition of the activity of vestibular nuclei, helping to restore proper balance and decrease in vertigo symptoms.

InChI:InChI=1/C8H12N2.2CH4O3S/c1-9-7-5-8-4-2-3-6-10-8;2*1-5(2,3)4/h2-4,6,9H,5,7H2,1H3;2*1H3,(H,2,3,4)